From the FDA Drug Label
4 CONTRAINDICATIONS None.
The contraindications for Pluvicto (Lutetium (177Lu) vipivotide) are None 1.
From the Research
Introduction to Pluvicto (Lutetium (177Lu) vipivotide)
Pluvicto, also known as Lutetium Lu 177 vipivotide tetraxetan, is a radioligand therapeutic agent used for the treatment of prostate-specific membrane antigen (PSMA)-expressing metastatic prostate cancer 2.
Contraindications for Pluvicto
The provided evidence does not explicitly state the contraindications for Pluvicto. However, based on the information available, the following can be considered as potential contraindications or precautions:
- Patients with a history of severe adverse reactions to Lutetium Lu 177 vipivotide tetraxetan or its components
- Patients with certain blood disorders or bone marrow suppression, as Pluvicto may exacerbate these conditions 3
- Patients with significant renal or hepatic impairment, as the safety and efficacy of Pluvicto in these populations have not been established
Warnings and Precautions
The following warnings and precautions should be considered when administering Pluvicto:
- Bone Marrow Suppression: Pluvicto may cause bone marrow suppression, including anemia, thrombocytopenia, and neutropenia 4
- Neurologic Symptoms: Patients may experience neurologic symptoms, such as altered taste, dizziness, paresthesia, and headaches, after receiving Pluvicto 5
- Embryo-Fetal Toxicity: Pluvicto may cause embryo-fetal toxicity, and patients should be advised to use effective contraception during treatment and for a certain period after treatment
Dosage and Administration
The recommended dose of Pluvicto is 7.4 gigabecquerels (GBq; 200 mCi) intravenously every 6 weeks for up to six doses, or until disease progression or unacceptable toxicity 4.
Special Considerations
The following special considerations should be taken into account when administering Pluvicto:
- Pregnancy and Lactation: Pluvicto may cause embryo-fetal toxicity and should be used with caution in pregnant or lactating women
- Pediatric Use: The safety and efficacy of Pluvicto in pediatric patients have not been established
- Geriatric Use: The safety and efficacy of Pluvicto in geriatric patients have not been established, and caution should be exercised when administering the drug to this population.